[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.249.15. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Original Contribution
January 1998

Selegiline Is Ineffective in a Collaborative Double-blind, Placebo-Controlled Trial for Treatment of Amyotrophic Lateral Sclerosis

Author Affiliations

From the Departments of Neurology, The Neurological Institute, Columbia-Presbyterian Medical Center, New York, NY (Drs Lange, Diamond, and Younger and Ms Murphy), and Baylor College of Medicine, Houston, Tex (Ms Appel and Drs Lai and Appel).

Arch Neurol. 1998;55(1):93-96. doi:10.1001/archneur.55.1.93
Abstract

Background  The cause of amyotrophic lateral sclerosis (ALS) is not known, and there is no effective treatment. Cell death may be caused by oxidative damage. Selegiline hydrochloride (Eldepryl) is a monoamine oxidase-B inhibitor with antioxidant properties.

Objective  To determine if selegiline affects the clinical course of patients with ALS.

Design  Six-month, double-blind, placebo-controlled study of 133 patients with classical ALS and symptoms for less than 3 years. The primary end point to indicate effectiveness was the rate of change of the Appel ALS total score, an index of disease severity that incorporates strength and function in limbs, respiratory function, and bulbar function.

Results  Of the 133 patients, 67 were randomized to receive selegiline and 66 to receive placebo. One hundred four patients (53 in the selegiline group and 51 in the placebo group) completed the 6-month trial. Both groups were comparable for baseline characteristics and mean Appel ALS total score (70.5 points for the selegiline group and 70.6 for the placebo group). There was no difference in the rate of progression as measured by the Appel ALS total score, showing an average increase of 22 points in 6 months. The monthly rate of change was 3.4 for the selegiline group and 3.5 for the placebo group. There was 1 adverse reaction: worsening depression. Seven patients died during the study (4 in the selegiline group and 3 in the placebo group).

Conclusion  Selegiline treatment had no significant effect on the rate of clinical progression or outcome of ALS.

×